Protara Q4 net loss widens on higher R&D spend

Protara Therapeutics, Inc. +1.39%

Protara Therapeutics, Inc.

TARA

5.11

+1.39%


Overview

  • Biotechnology firm's Q4 net loss was $17.3 mln, driven by increased R&D expenses

  • Company completed $86 mln public offering, cash supports operations into 2028


Outlook

  • Protara to provide regulatory update for TARA-002 in LMs in 1H 2026


Result Drivers

  • FINANCIAL POSITION - Completed $86 mln public offering, cash supports operations into 2028


Company press release: ID:nGNX10t3qG


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 EPS

-$0.37

Q4 Net Income

-$17.31 mln

Q4 Income from Operations

-$19.08 mln

Q4 Operating Expenses

$19.08 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Protara Therapeutics Inc is $25.00, about 334.8% above its March 9 closing price of $5.75


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.